Reported Earlier, Legend Biotech CARVYKTI Delivers Improved MRD Negativity And Overall Survival Benefits In Phase 3 CARTITUDE-4 Study
Reported Earlier, Legend Biotech CARVYKTI Delivers Improved MRD Negativity And Overall Survival Benefits In Phase 3 CARTITUDE-4 Study
早前報道，傳奇生物CARVYKTI在三期CARTITUDE-4研究中顯示出改善的微小殘留病陰性率和總體生存益處。
- 89 percent of evaluable patients achieved minimal residual disease (MRD) negativity with CARVYKTI after three-year follow-up in CARTITUDE-4 study; the majority in less than 2 months
- Results add to the overall survival (OS) benefit recently reported making CARVYKTI the first and only cell therapy to significantly extend OS versus standard therapies in multiple myeloma
- Landmark Phase 3 CARTITUDE-4 study data featured as an oral presentation at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition
- 在CARTITUDE-4研究中，經過三年跟蹤，89%的可評估患者在使用CARVYKTI後達到了微小殘留病（MRD）陰性；大多數患者在不到2個月內達成這一結果。
- 結果補充了最近報告的總體生存（OS）益處，證明CARVYKTI是首個也是唯一一個在多發性骨髓瘤中相比標準療法顯著延長OS的電芯療法。
- 作爲口頭報告，CARTITUDE-4的里程碑III期研究數據在第66屆美國血液學會（ASH）年會和博覽會上進行了展示。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。